Skip to content

6 mg/ml

DRUG7 trials

Sponsors

Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy, Swiss Group for Clinical Cancer Research, NSABP Foundation Inc., Iperboreal Pharma S.r.l., Rheinische Friedrich-Wilhelms-Universitaet Bonn

Conditions

Advanced throat and larynx cancerCystic FibrosisEnd-Stage Kidney DiseaseHER2 negative breast cancerN2)Patients with early breast cancerResectablelocally advanced non-small cell lung cancer (NSCLC

Phase 2

A phase II study of preoperative stereotactic radiation therapy boost combined with short-course immunotherapy (pembrolizumab versus placebo, randomized, double-blind) and standard chemotherapy in patients with newly diagnosed HER2-negative non-metastatic breast cancer with lack of early metabolic response in 18-fluorodeoxyglucoseFDG-PET/CT after 1st chemoterapy cycle
RecruitingCTIS2023-504145-31-00
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut BadawczyHER2 negative breast cancer
Start: 2024-06-10Target: 78Updated: 2024-02-21
Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III(N2) non-small cell lung cancer (NSCLC). A multicenter phase II trial.
Active, not recruitingCTIS2023-504536-18-00
Swiss Group for Clinical Cancer Researchlocally advanced non-small cell lung cancer (NSCLC, N2), Resectable
Start: 2024-07-31Target: 10Updated: 2025-10-22
A phase II trial to assess the activity and tolerability of Thymosin alpha 1 in Cystic Fibrosis Patients
CompletedCTIS2024-518102-41-00
Sciclone Pharmaceuticals International (SG) Pte. Ltd.Cystic Fibrosis
Start: 2021-12-07End: 2025-03-07Target: 24Updated: 2025-02-18
The asssessment of the efficacy of induction radiochemotherapy using low doses of ionizing radiation (iCHRTL) in the treatment of patients with advanced throat and larynx cancer
RecruitingCTIS2024-517480-23-00
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut BadawczyAdvanced throat and larynx cancer
Start: 2022-02-17Target: 40Updated: 2025-01-31
Prospective randomized Phase II trial on Induction Immunochemotherapy followed by surgery or definitive chemoradiation and consolidation Durvalumab (MEDI4736) in resectable and borderline resectable stage IIIA/B NSCLC
RecruitingCTIS2024-516367-80-00
Rheinische Friedrich-Wilhelms-Universitaet Bonnresectable and borderline resectable stage IIIA/B NSCLC
Start: 2025-04-24Target: 176Updated: 2025-10-10

Phase 3

Related Papers